NCT03136146View on ClinicalTrials.gov

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Recurrent Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaRecurrent Burkitt LeukemiaRecurrent Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt LeukemiaRefractory Burkitt LymphomaRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory Lymphoblastic Lymphoma
Interventions
DRUG

Bortezomib

Given SC

DRUG

Clofarabine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Etoposide

Given IV

BIOLOGICAL

Ofatumumab

Given IV

BIOLOGICAL

Pegfilgrastim

Given SC

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate Liposome

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER